[go: up one dir, main page]

NO20015227D0 - Fremgangsmåte for å öke effektiviteten til anti-cancer midler - Google Patents

Fremgangsmåte for å öke effektiviteten til anti-cancer midler

Info

Publication number
NO20015227D0
NO20015227D0 NO20015227A NO20015227A NO20015227D0 NO 20015227 D0 NO20015227 D0 NO 20015227D0 NO 20015227 A NO20015227 A NO 20015227A NO 20015227 A NO20015227 A NO 20015227A NO 20015227 D0 NO20015227 D0 NO 20015227D0
Authority
NO
Norway
Prior art keywords
effectiveness
increase
steps
cancer agents
cancer
Prior art date
Application number
NO20015227A
Other languages
English (en)
Other versions
NO20015227L (no
Inventor
Steven M Piver
David Silver
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of NO20015227D0 publication Critical patent/NO20015227D0/no
Publication of NO20015227L publication Critical patent/NO20015227L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
NO20015227A 1999-04-27 2001-10-25 Fremgangsmate for a oke effektiviteten til anti-cancer midler NO20015227L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/300,124 US6171620B1 (en) 1999-04-27 1999-04-27 Method of enhancing the efficacy of anti-tumor agents
PCT/US2000/011000 WO2000064455A1 (en) 1999-04-27 2000-04-24 Method of enhancing the efficacy of anti-tumor agents

Publications (2)

Publication Number Publication Date
NO20015227D0 true NO20015227D0 (no) 2001-10-25
NO20015227L NO20015227L (no) 2001-12-27

Family

ID=23157813

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015227A NO20015227L (no) 1999-04-27 2001-10-25 Fremgangsmate for a oke effektiviteten til anti-cancer midler

Country Status (18)

Country Link
US (3) US6171620B1 (no)
EP (1) EP1212068A4 (no)
JP (1) JP2002542296A (no)
KR (1) KR100693796B1 (no)
CN (1) CN1188137C (no)
AU (1) AU781301B2 (no)
BG (1) BG64940B1 (no)
BR (1) BR0010082A (no)
CA (1) CA2368618C (no)
HU (1) HUP0200840A3 (no)
IL (1) IL146012A0 (no)
MX (1) MXPA01010899A (no)
NO (1) NO20015227L (no)
NZ (1) NZ514521A (no)
PL (1) PL350918A1 (no)
RU (1) RU2271829C2 (no)
WO (1) WO2000064455A1 (no)
ZA (1) ZA200108012B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2232613T3 (es) 2000-04-26 2005-06-01 Cellegy Pharmaceuticals, Inc Formulaciones y metodos de utilizacion de agentes mimeticos del oxido nitrico contra un fenotipo celular maligno.
US20050142217A1 (en) * 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
AU2003263552A1 (en) * 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
BRPI0409133B8 (pt) 2003-04-08 2021-05-25 Progenics Pharm Inc preparações farmacêuticas estavéis compreendendo metilnaltrexona
DE10361813A1 (de) * 2003-12-30 2005-09-08 Bionethos Holding Gmbh Verfahren zur Regeneration von Gewebe
CA2600350C (en) * 2005-03-07 2015-02-10 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
EP2120998B1 (en) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modified erythropoietin polypeptides and uses thereof for treatment
CA2682125C (en) 2007-03-29 2015-06-16 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
BRPI0809579B8 (pt) 2007-03-29 2021-05-25 Progenics Pharm Inc formas cristalinas e seus usos
EP2139890B1 (en) 2007-03-29 2014-06-25 Wyeth LLC Peripheral opioid receptor antagonists and uses thereof
KR101581480B1 (ko) 2008-02-06 2015-12-30 프로제닉스 파머슈티컬스, 인코포레이티드 (ｒ),(ｒ)-2,2'-비스-메틸날트렉손의 제조법 및 용도
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
EP2310038A4 (en) * 2008-05-15 2012-03-14 Edison Pharmaceuticals Inc TREATMENT OF HEARING AND BALANCE DISORDERS WITH COMPOUNDS HAVING ERYTHROPOIETIN ACTIVITY
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
PL230756B1 (pl) * 2015-09-11 2018-12-31 Univ Medyczny W Bialymstoku Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu
WO2019083023A1 (ja) * 2017-10-26 2019-05-02 国立大学法人筑波大学 癌の治療に使用するための組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
JPH1067678A (ja) * 1996-06-20 1998-03-10 Chugai Pharmaceut Co Ltd 肝疾患治療用医薬組成物
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury

Also Published As

Publication number Publication date
NO20015227L (no) 2001-12-27
IL146012A0 (en) 2002-07-25
AU4486300A (en) 2000-11-10
CN1352561A (zh) 2002-06-05
CN1188137C (zh) 2005-02-09
MXPA01010899A (es) 2003-06-24
WO2000064455A1 (en) 2000-11-02
US20010000730A1 (en) 2001-05-03
US20020198153A1 (en) 2002-12-26
US6620779B2 (en) 2003-09-16
HUP0200840A2 (hu) 2002-07-29
BG106057A (en) 2002-04-30
KR20020000557A (ko) 2002-01-05
CA2368618C (en) 2011-03-01
ZA200108012B (en) 2003-03-26
HUP0200840A3 (en) 2003-04-28
US6171620B1 (en) 2001-01-09
RU2271829C2 (ru) 2006-03-20
EP1212068A4 (en) 2007-03-14
PL350918A1 (en) 2003-02-10
JP2002542296A (ja) 2002-12-10
AU781301B2 (en) 2005-05-12
KR100693796B1 (ko) 2007-03-12
BR0010082A (pt) 2002-01-15
US6426094B2 (en) 2002-07-30
NZ514521A (en) 2003-07-25
CA2368618A1 (en) 2000-11-02
EP1212068A1 (en) 2002-06-12
BG64940B1 (bg) 2006-10-31

Similar Documents

Publication Publication Date Title
NO20015227D0 (no) Fremgangsmåte for å öke effektiviteten til anti-cancer midler
NO20015773L (no) Kryssreferanser til relaterte söknader
EE200100483A (et) Põletikuvastaste vahenditena kasutatavad ühendid
IS5997A (is) Heteróarýl-setnar kínólín-2-ón afleiður gagnlegarsem miðlar gegn krabbameini
IS6340A (is) Vatnsgel-knúið lyfjaskammtaform
DE60013221D1 (de) Fotopolymerisierbare Zusammensetzung
EE200100393A (et) Vähivastaste vahenditena kasulikud asendatud bitsüklilised derivaadid
EE200200172A (et) Ühendid isheemia ravimiseks
CY2012003I2 (el) Αντισωματα που συνδεονται ανοσοειδικως προς blys
AR023440A1 (es) Composiciones antitranspirantes
ID20637A (id) Metode untuk menghambat pembentukan sulfida biogenik
ID29149A (id) Komposisi adjuvan
ID29785A (id) Komposisi-komposisi sampo
IS6575A (is) Hýdroxýfenýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
IS5333A (is) Prostaglandínafleiður án hliðarverkana til að meðhöndla gláku
ATE257691T1 (de) Schweisshemmende zusammensetzungen
NO20006371D0 (no) Langkjedede alkoholer tilsatt til sterolforbindelser
DE50011908D1 (de) 16-hydroxyestratriene als selektiv wirksame estrogene
NO20013769D0 (no) Kalsilytiske forbindelser
IS6563A (is) Hýdroxýfenýl-píperasinýl-metýl-bensamíðafleiður til að meðhöndla sársauka
IS6574A (is) Kínólinýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
DE59914416D1 (de) Silikatmasse
FI20010332L (fi) Parannus värinäpumppuun
NO20010842L (no) Forbindelseselement for sammenkobling av to komponenter
ITTO20000210A0 (it) Dispositivo per favorire l'unificazione costruttiva di cartucce per apparecchi idraulici.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application